



ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2023 #35

September 29, 2023

INSIDE:

| | |
|--|---|
| WORD IN WASHINGTON | 2 |
| Registration Opens for ADRP's October Webinar | 4 |
| SAVE THE DATE: ABC WELC Webinar Featuring Dr. Meghan D. Kinter | 4 |
| RESEARCH IN BRIEF | 5 |
| PEOPLE | 5 |
| MEMBER NEWS | 6 |
| GLOBAL NEWS | 7 |
| COMPANY NEWS | 7 |
| CALENDAR | 8 |
| EQUIPMENT AVAILABLE | 9 |
| POSITIONS | 9 |

FDA Proposed Rule for Laboratory Developed Tests

Today, the U.S. Food and Drug Administration (FDA) [announced](#) the [upcoming publication](#) (October 3rd) of a proposed rule to make explicit that *in vitro* diagnostic products (IVDs) are medical devices under the Federal Food, Drug, and Cosmetic Act, including when the manufacturer of the IVD is a laboratory. In addition to this change, the agency proposed a policy under which the FDA intends to provide greater oversight of laboratory developed tests (LDTs), through a phaseout of its general enforcement discretion approach to LDTs, so that IVDs manufactured by a laboratory would generally fall under the same enforcement approach as other IVDs. Historically, the FDA has exercised enforcement discretion over most LDTs, meaning the agency generally has not enforced applicable requirements with respect to most LDTs.

A 60-day comment period will follow the publication of the proposed rule in the *Federal Register* on October 3rd with comments due by December 4th. The agency also explained that it is aware of arguments that the medical expertise of laboratorians or requirements under clinical laboratory improvement amendments (CLIA) already provide adequate oversight of IVDs offered as LDTs. However, FDA noted that their review of the evidence indicates otherwise, and suggests that under the current scheme, the healthcare community lacks adequate assurances about the safety and effectiveness of IVDs offered as LDTs. Additionally, although laboratories that offer LDTs are also subject to CLIA, which is primarily administered by the Centers for Medicare & Medicaid Services (CMS), CLIA is not a substitute for FDA oversight.

While the agency's approach described in the proposed rule would phaseout its general enforcement discretion approach for most LDTs, the FDA does not intend to sweep in certain tests that were excluded from the general enforcement discretion approach, as reflected in compliance patterns, multiple public FDA actions and communications, or both. These tests include those that are intended as blood donor screening or human cells, tissues, and cellular and tissue-based products (HCT/Ps) donor screening tests required for infectious disease testing under 21 CFR 610.40 and 1271.80(c), respectively, or for determination of blood group and Rh factors required under 21 CFR 640.5.

The FDA further explained that under the cited regulations, a blood or HCT/P establishment must not use a test for the purposes listed here unless the test is licensed, approved, or cleared by FDA for such use. Blood and HCT/P establishments must register with FDA and are subject to FDA inspection. The agency also added that the general enforcement discretion approach for LDTs has never applied to these

(continued on page 2)



FDA LDTs Proposed Rule (continued from page 1)

tests because these tests are a critical part of the overall process of ensuring the safety of blood and blood components and HCT/Ps by preventing infectious disease transmission and incompatible blood transfusions which can have life-threatening consequences. Based on FDA's experience, establishments have been generally complying with these requirements, and they are not proposing to change that approach.

America's Blood Centers (ABC) in consultation with the ABC QA Blood Regulatory Review and the Scientific, Medical, and Technical Committees, and the ABC Policy Council will further review the rule to assess the impact on the policies and procedures of blood centers. ABC also plans to submit comments on the proposed rule. Members are encouraged to send suggested language for inclusion to [Justine Coffey, JD](#), director of Regulatory Affairs and Public Policy. Comments should be sent to ABC by November 3rd, to ensure sufficient time for inclusion. Additionally, ABC member centers are encouraged to send their own letters on the draft guidance to FDA.

(Sources: FDA [News Release](#), 9/29/23; FDA [Proposed Rule](#), 10/3/23; MCN 23-082, 9/29/23) 💧

WORD IN WASHINGTON



Members of America's Blood Centers (ABC) gathered in Washington, D.C. this week to meet with leaders from the U.S. Department of Health and Human Services (HHS), the Biomedical Advanced Research and Development Authority (BARDA), and the Office of the Assistant Secretary for Preparedness and Response (ASPR). The discussions centered on national surge capacity for the U.S. blood supply. Attendees from ABC member blood centers pictured are Juan Cotto (Bloodworks Northwest), Billy Weales (The Blood Center), and Adrienne Mendoza (South Texas Blood & Tissue Center). Other attendees from ABC member blood centers who participated in the meeting but

are not in the photo include John Hagins (The Community Blood Center), Marc Lewis (Gulf Coast Regional Blood Center), Martin Grable (OneBlood), Amanda Farrell (ADRP President), and Jed Gorlin, MD, MBA (ABC Chief Medical Officer).

(continued on page 3)

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2023 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers

Chief Executive Officer: Kate Fry
 Chief Medical Officer: Jed Gorlin
 Editor: Mack Benton
 Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: \$390

Send subscription queries to
memberservices@americasblood.org
 America's Blood Centers
 1717 K St. NW, Suite 900, Washington, DC 20006
 Phone: (202) 393-5725
 Send news tips to newsletter@americasblood.org.

WORD IN WASHINGTON (continued from page 2)

The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) is [collaborating](#) with the University of Pittsburgh School of Medicine on a clinical trial, “to identify blood transfusion best practices for pediatric patients with traumatic injury in the Massive Transfusion in Children-II (MATIC-II) Phase 3 clinical trial. The trial will include injured children with hemorrhagic shock anticipated to require massive blood transfusion. This randomized, controlled, multicentered clinical trial will help address a research gap by identifying pediatric-specific transfusion methods.” According to an announcement from BARDA, “[t]he trial will examine the safety and effectiveness of transfusion with whole blood versus component therapy (CT), as well as tranexamic acid (TXA), a drug that helps prevent bleeding, vs. placebo. The current standard of care for blood transfusions is to transfuse red blood cells, frozen plasma, and platelet concentrates separately in a balanced proportion to address specific deficiencies and clotting abnormalities...This effort aligns with BARDA’s overarching strategy, outlined in the [2022-2026 Strategic Plan](#), to protect all members of our communities against an evolving threat landscape. This includes supporting development of MCMs to address critical gaps in the treatment of children.”

(Source: BARDA [Announcement](#), 9/21/23)

President Biden has [signed](#) House Resolution 2544 “Securing the U.S. Organ Procurement and Transplantation Network Act” into law on September 22nd. The legislation “allows for the award of multiple grants, contracts, or cooperative agreements to operate the Organ Procurement and Transplantation Network.” Earlier this month, the Centers for Medicare and Medicaid Services (CMS) and the Health Resources and Services Administration (HRSA) [announced](#) the formation of an Organ Transplantation Affinity Group (OTAG): Strengthening accountability, equity, and performance. According to the announcement, “this collaborative seeks to drive improvements in donations, clinical outcomes, system improvement, quality measurement, transparency, and regulatory oversight.” OTAG published five goals that include:

- reduce variation of pre-transplant and referral practices;
- increase the availability and use of donated organs;
- increase accountability for organ procurement and matching;
- promote equitable access to transplants; [and]
- empower patients, families, and caregivers to actively engage in the transplant journey.”

(Sources: White House [Announcement](#), 9/22/23; CMS and HRSA [Announcement](#), 9/15/23) 💧

NEW on CollABORate**COLLABORATE**

SHARE STRATEGIC ADVICE | SOLVE CHALLENGES | DEVELOP NEW APPROACHES

Recent discussion topics on the ABC [CollABORate](#) Online Member Community include:

- [Biannual QC of Mobile Transport Containers](#) (QUALITY BYTES)
- [Saline Washed Apheresis Platelets](#) (ALL MEMBER FORUM)
- [Post-donation Callback Instructions](#) (MEDICAL ISSUES)

ABC members are encouraged to [login](#) and join the conversations today!



America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

Registration Opens for ADRP's October Webinar

Join ADRP, the Association for Blood Donor Recruitment Professionals on Wednesday, October 25th at 1 p.m. EDT for the “[Innovations in Donor Recruitment and Inventory Growth](#)” webinar. This event will feature successful case studies from blood center professionals as they describe the creative programs and incentives that their blood centers have implemented, while taking risks that ultimately resulted in substantial inventory boosts. This strategy ensured that their local hospital partners consistently had blood products on their shelves, especially during challenging times of the year. [Registration](#) is open. Donor recruitment professionals will find this webinar particularly enriching, as speakers share data, results, and new and effective ways that can help you meet your collection goals. Join us to hear speakers from:

- Our Blood Institute;
- LifeSouth Community Blood Centers;
- ConnectLife; and
- Memorial Blood Centers.

SAVE THE DATE: ABC WELC Webinar Featuring Dr. Meghan D. Kinter

America's Blood Centers (ABC) [Women's Executive Leadership Community](#) (WELC) will host its first [webinar](#), titled “Taming the Tyranny of the Urgent,” on October 26th at 2 p.m. EDT. Meghan D. Kinter, PhD, will be the guest speaker. This webinar will feature breakout sessions for attendees and a question-and-answer session with Dr. Kinter who has, according to her bio, spent more than two decades “expertly guid[ing] businesses and individuals through the complexities of their challenges, helping them navigate from feeling ‘stuck’ to achieving clarity and momentum.” By the end of the event, attendees will discover the Power of the 3Ms – Mindful Mindset, Managing Time, and Mastering Habits, understand the psychology behind urgency and its impact on productivity, develop a resilient, proactive approach to daily challenges, and curate a personal toolkit of habits, tools, and strategies to optimize every day. The WELC is a complimentary offering open to all employees of ABC member blood centers and active ABC industry partners. Through this initiative, ABC strives to empower leaders throughout the blood community through networking and professional development. ABC encourages eligible individuals to [join](#) WELC and its [LinkedIn Community](#), and share this information with those who may be interested. 💡

ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!



RESEARCH IN BRIEF

Nutrient Supplementation Culture Media Improves Growth of *Cutibacterium acnes* in Platelets. A study in *Vox Sanguinis* examined, “the ability of pure oleic acid, T80 and the BD Difco Supplement VX (BDVx) to improve *Cutibacterium acnes* (*C. acnes*) detection.” The authors explained that, “[four *C. acnes* strains] were used for this study...A stock solution consisting of T80 in anaerobic culture bottles (BPN) media extricated from BPN bottles was prepared.” *C. acnes* was “tested at two bacterial loads (10 and 100 colony forming units (CFU)/bottle)...The bottles were incubated in the BACT/ALERT 3D system until a positive flag was obtained or for a maximum of 10 days.” The researchers noted that, “[t]wo concentrations of T80 (four and two percent, v/v) reduced detection times in all four isolates at both bacterial loads tested.” “[S]ignificant reductions were observed for *C. acnes* BPNBT-19195 tested at 10 CFU/bottle with T80 4 percent ($p = 0.015$) and 2 percent ($p = 0.049$), and at 100 CFU/bottle with T80 2 percent ($p = 0.030$)...Similarly, significantly lower times to detection were observed for isolate BPNBT-19422 tested at 10 CFU/bottle with T80 four percent ($p = 0.044$), 0.1 percent ($p = 0.007$) and 0.05 percent ($p = 0.044$)...Significant reduction in times to detection was observed for BPNBT-153 of 2.23 days ($p < 0.005$) and BPNBT-195 of 1.26 days ($p < 0.005$) from diluted plasma in T80-supplemented BPN Bottles.” Additionally, the study found that, “[s]upplementation of BPN media with BDVx supplement resulted in a reduction in the time to detection of the two *C. acnes* isolates tested BPNBT-19153 (0.62 ± 0.26 days, $p = 0.048$) and BPNBT-19195 (1.15 ± 0.29 days, $p = 0.030$) in platelet concentrates (PCs) suspended in 100 percent plasma.” The authors concluded that the study, “provided strong evidence that growth and detection of *C. acnes* can be improved during PC screening with the BACT/ALERT system. Reduction in detection times by 24 h could provide blood suppliers with the ability to recall *C. acnes*-contaminated products before they are transfused into vulnerable patients, thereby improving the safety of the blood supply.”

Citation: Kumaran, D., Ramirez-Arcos, S. “[Nutrient supplementation of culture media improves the detection of *Cutibacterium acnes* in platelet components by an automated culture system.](#)” *Vox Sang.* 2023

Contributed by Richard Gammon, MD, Medical Director at OneBlood 💧

PEOPLE

Marius Witzoe is joining Central California Blood Center (CCBC), based in Fresno, and serving the Central Valley and beyond, as senior director for Business Development and Innovation. According to CCBC announcement, Mr. Witzoe spent, “his last eight years with Cerus Corporation, leading commercialization efforts in the western region of the U.S. for the INTERCEPT Blood System portfolio. He has over 20 years of blood industry experience starting with Haemonetics, then with Cerus in Europe, Canada, and the U.S.” CCBC President and Chief Executive Officer Christopher Staub added in the announcement, “[w]e are delighted to have Marius come aboard. We have ambitious expectations for growth in our blood donor base. Marius will also strengthen our capabilities to develop and expand innovative programs for our patients and for mission-compatible revenue streams for sustainability.”

(Source: CCBC Announcement, 9/29/23)



[Rebecca Cardigan, PhD](#) has been elected as president of the BEST Collaborative beginning October 11th. According to a news release from the organizations, Dr. Cardigan is a, “consultant clinical scientist in Haematology, currently national head of Components Development for NHS Blood & Transplant, and affiliated associate professor, Department of Haematology, University of Cambridge. She is responsible for the laboratory and clinical evaluation of major changes to how blood for transfusion is produced, stored, and monitored in England.” In the news release, Dr. Cardigan stated, “it’s a great hon[o]r for me to become

(continued on page 6)



PEOPLE (continued from page 5)

President of BEST. As a scientific member of BEST for over a decade, and team leader for conventional components since 2018, I am a long-term supporter of its work, and a firm advocate of its collaborative model. BEST is a unique organi[z]ation within our particular community, bringing together industry, blood operators, and academics like no other. I look forward to building on the strong foundations that the previous Presidents have established in ensuring BEST is an impactful organi[z]ation.” Her term will be three years. Dr. Cardigan has “led numerous research projects that have subsequently been translated into routine practice in the NHS and has made significant contributions to setting national guidelines/policy as Chair of the United Kingdom (UK) Standing Advisory Committee on Blood Components for 7 years and Deputy Director for the UK Joint Professional Advisory Committee for six years. She received the British Blood Transfusion Society Race & Sanger Award in 2007 for an outstanding contribution to transfusion medicine and Kenneth Goldsmith Award in 2019 for contribution to research in the field of transfusion. She is a Consultant Civilian Advisor to the UK Ministry of Defen[s]e and a member of the Safety Advisory Board for Héma-Québec. She has published over 100 papers in the area of h[e]mostasis and transfusion and was section Editor for *Vox Sanguinis*, the official journal of the International Society for Blood Transfusion for eight years.”

(Source: BEST Collaborative [News Release](#), 9/21/23)

Jonathan Stefely, MD, PHD has been announced as the 31st recipient of the Bio-medical Excellence for Safer Transfusion (BEST) Collaborative Scott Murphy Memorial Award Lectureship. He is an attending physician and research fellow, Transfusion Medicine and Cell and Molecular Biology, at Massachusetts General Hospital (Boston, Mass.). Dr. Stefely will deliver a lecture on, “[a]n automated red cell morphology differential-the RBC-diff-as a new diagnostic and prognostic tool for transfusion medicine and hematology” during the 66th Meeting of BEST in Nashville, Tenn., to be held October 10th-11th. A list of prior award recipients and their presentation titles can be found on the BEST [website](#).



(Source: BEST [News Release](#), 9/7/23) 💧

MEMBER NEWS

Mississippi Blood Services has joined the Alliance for Community Transfusion Services (ACTS). According to a joint news release, the blood center becomes ACTS’ 16th member. “We’re excited to add Mississippi Blood Services as a member of our alliance,” said Nelson Hellwig, MBA, chief executive officer of ACTS, in the news release. “With a history of great community support and strong commitment to the community blood center model, they will further strengthen our alliance of leading blood centers.” Mississippi Blood Services’ Chief Executive Officer Christopher Swafford added in the news release, “We are extremely honored to join the Alliance for Community Transfusion Services. Being part of this alliance will allow us to better serve our community through collaborative efforts with our fellow blood center members.” ACTS was established in 2010 to “strengthen relationships between community blood programs and their local hospitals and stakeholders.”

(Source: ACTS News Release, 9/28/23)

New York Blood Center Enterprises’ Comprehensive Cell Solutions and **Vitalant’s** Cell Therapy Lab recently [partnered](#) with the National Marrow Donor Program® (NMDP)/Be The Match®. According to the news release from NMDP, the partnerships “add industry-leading expertise in cryopreservation and storage of hematopoietic stem cells and will increase donor availability.” Melissa Marlowe, vice president

(continued on page 7)



MEMBER NEWS (continued from page 6)

of Clinical Services Administration at Vitalant, stated in the news release, “We are proud to collaborate with NMDP cryopreservation service to remove barriers that otherwise may prevent a patient’s transplant.” Jay Mohr, executive vice president and chief business officer at New York Blood Center Enterprises, added, “[w]e are delighted to expand our work with the NMDP/Be The Match and become a partner in its cryopreservation service. Together, we will give transplant physicians confidence that the high-quality bone marrow or PBSC product they need will be available from the donor they requested in the timeframe that works best for their patient. This partnership will build on Comprehensive Cell Solutions’ mission to change lives, one patient at a time.”

(Source: NMDP [News Release](#), 9/26/23) ◆

GLOBAL NEWS

Officials in Wales have proposed [revising](#) the country’s cell and tissue donation eligibility criteria. According to the announcement, the country is removing “restrictions preventing some LGBTQ+ [individuals] from donating tissue, surgical bone and stem cells.” Welsh Minister Eluned Morgan added in the news release, “I am pleased to announce the implementation of the recommendations will extend this to tissue and cell donations. We need as many donors as possible, and this move will enable more people to make these priceless donations. The changes will ensure a fairer and more up-to-date assessment of risk is applied to all donors, without discrimination.” The new recommendations were proposed after a review by the For the Assessment of Individuali[z]ed Risk (FAIR) Steering Group, “a United Kingdom (UK)-wide collaboration including representatives from all UK blood services, medical, scientific and academic experts, LGBTQ+ groups, as well as a selection of patients, donors and their families.” In 2020, donor eligibility criteria for blood and platelet donors were revised based on recommendations from the FAIR Steering Committee, “so that all donors, regardless of gender, are now asked questions about sexual behavi[o]rs, focused mainly on the last three months. These changes allowed more people from LGBTQ+ communities to donate.”

(Source: Welsh Government [News Release](#), 9/18/23) ◆

COMPANY NEWS

Moderna Inc. recently announced positive findings from an ongoing clinical trial of its investigational mRNA universal influenza vaccine. A company news release explained, “[the investigational mRNA vaccine candidate] demonstrated an acceptable safety and tolerability profile across all clinical trials to date, including three phase III trials, and independent data and safety monitoring boards (DSMBs) have raised no safety concerns.” According to the announcement, “an interim analysis of the P303 study, [the investigational mRNA vaccine candidate] met all co-primary endpoints across all four A and B strains (A/H1N1, A/H3N2, influenza B/Yamagata, B/Victoria). Higher HAI geometric mean titers and seroconversion rates were observed for all four strains compared to a licensed comparator (Fluarix). Local and systemic solicited adverse reactions were similar to those reported in previous [studies]. Improved immunogenicity was observed across age groups, and importantly, was seen in older adults. [The investigational vaccine candidate] also elicited higher HAI titers against A/H1N1, A/H3N2, B/Victoria, and comparable titers to B/Yamagata compared to Fluzone HD in a separate phase I/II head-to-head study. Consultations with regulators on a potential licensing package are currently ongoing based on these data.”

(Source: Moderna, Inc. News Release, 9/13/23) ◆





Upcoming ABC Webinars & Virtual Events – Don't Miss Out!

- **ADRP Webinar: Innovations in Donor Recruitment and Inventory Growth** – Oct. 25. [Registration](#) is open. More information available [here](#).
- **ABC Women's Executive Leadership Community (WELC) Webinar** – Oct. 26. More information and a link to registration are available to ABC Members in [MCN 23-081](#).
- **2023 ADRP International Showcase** – Nov 15. [Registration](#) is open. More information available [here](#).



CALENDAR

***Note to subscribers:** Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)*

2023

Oct. 9-11. **Advanced Medical Technology Association (AdvaMed) The MedTech Conference, Anaheim, Calif.** [Registration](#) is open. More information available [here](#).

Oct. 10-11. **Biomedical Excellence for Safer Transfusion (BEST) Meeting LXVI, Nashville, Tenn.** More information available [here](#).

Oct. 11-14. **Sickle Cell Disease Association of America 51st Annual National Convention, Arlington, Va.** [Registration](#) is open. More information available [here](#).

Oct. 14-17. **AABB Annual Meeting, Nashville, Tenn.** [Registration](#) is open. More information available [here](#).

Oct. 18-20. **American Society for Clinical Pathology (ASCP), Long Beach, Calif.** More information available [here](#).

Oct. 25. **ADRP, The Association for Blood Donor Professionals Webinar: Innovations in Donor Recruitment and Inventory Growth.** [Registration](#) is open. More information available [here](#).

Oct. 26. **America's Blood Centers (ABC) Women's Executive Leadership Community (WELC) Webinar.** More information and a link to registration are available [here](#).

Oct. 31. **U.S. Food and Drug Administration (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee Meeting (Virtual).** More information available [here](#).

Nov. 13-14. **U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA) Industry Day 2023. (Hybrid), Washington, D.C.** [Registration](#) is open. More information available [here](#).

Nov 15. **ADRP, The Association for Blood Donor Professionals International Showcase (Virtual).** [Registration](#) is open. More information available [here](#).

(continued on page 9)



CALENDAR (continued from page 8)

Nov. 18-21. **ISBT Regional Congress, Cape Town, South Africa.** [Registration](#) is open. More information available [here](#).

2024

Feb.7-8. **International Plasma and Fractionation Association & EBA Symposium on Plasma Collection and Supply. Leiden, Netherlands.** [Registration](#) is open. More information available [here](#).

Mar. 4-6. **ABC Annual Meeting, Arlington, Va.** More information available [here](#).

April 12-13. **BEST Meeting, Amsterdam, Netherlands.** More information coming soon.

May 14-16. **2024 ADRP Annual Conference, St. Louis, Mo.** More information available [here](#). ♦

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

EQUIPMENT AVAILABLE

For Sale. Two refurbished Aurora Plasmapheresis System devices with Certificate of Compliance for each device. Both devices have Software 2.0 installed. Asking for best offer. Location: Jackson, TN. Please contact LaTrina Morman, (731) 427-4431, or email latrinamorman@lifelinebloodserv.org.

For Sale. Two NEW Aurora Plasmapheresis System devices with Certificate of Compliance. NEVER USED. Currently, both have Software 2.0 installed. Asking for best offer. Location: Jackson, TN. Please contact LaTrina Morman, (731) 427-4431, or email latrinamorman@lifelinebloodserv.org.

POSITIONS

Phlebotomist 2 – Donor Centers (Carter BloodCare).

Principal Accountability: The Phlebotomist 2 assists in smooth and efficient donor flow, determine donor acceptability, performs sterile venipuncture for the collection of blood, provides excellent customer service and ensures compliance with regulations and standard operating procedures throughout the donation process. In the absence of a supervisor, this position will oversee and assign responsibilities to collections staff, except for hiring and/or terminations. This includes effectively and discreetly solving personnel and donor problems, addressing procedural or behavioral problems, and making verbal or written reports to management. Additionally, the Phlebotomist 2 will be required to attend and complete annual leadership/development training resources, to mentor/assist with on-the-job development of new employees and subordinate staff. This position may be required to participate in special projects or programs. Regular full-time attendance is required during operational hours. Education: High school diploma or equivalent. Some college a plus. Experience: One-year general work experience, preferably working with the public, or education that includes comparable experience such as an internship or externship. Customer service experience required, intern

and/or externship experience will satisfy this requirement. Previous Phlebotomy 1, blood banking experience or medical field experience. Background in a highly regulated industry. Bilingual skills and CDL driver a plus. Equal Opportunity Employer: Disability/Veteran. Apply at www.carterbloodcare.org, click Careers & search for job # Phlebotomist 2.

Purchasing Manager. LifeSouth Community Blood Centers is seeking a highly skilled leader with proven management experience and a passion for making a difference. The Purchasing Manager at our headquarters location in Gainesville, FL is responsible for vendor selection, negotiation, establishment and maintenance of all purchased materials, supplies, equipment, and services used by the company. The Purchasing Manager oversees daily operations of the Purchasing team, is organized and decisive, and can motivate the team to reach daily and long-range goals. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

(continued on page 10)

POSITIONS (continued from page 9)

Employee Relations Manager. LifeSouth Community Blood Centers is seeking a highly skilled leader with proven management and HR experience, and a passion for making a difference. The Employee Relations Manager at our headquarters location in Gainesville, FL is responsible for facilitating employee relations and resolving personnel issues. The Employee Relations Manager deals with grievances and violations invoking disciplinary action, provides guidance, advice, and support to managers and employees on HR related issues, and oversees the work of eight Human Resources Coordinators. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

Immunohematology Reference Lab Manager. LifeSouth Community Blood Centers is seeking an individual who enjoys leading a team of lab professionals dedicated to providing high quality products and services for patients. Our Birmingham, AL IRL is supported by Board Certified Pathologists in Transfusion Medicine, and by LifeSouth's accredited HLA Lab, Molecular Lab, and IRLs in Gainesville, FL and Atlanta, GA. The IRL Manager is responsible for providing onsite day-to-day supervision of testing personnel, ensuring compliance with regulatory agency requirements, and reporting of test results under the direction of the laboratory director. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

Regional Manager. LifeSouth Community Blood Centers is seeking a highly skilled leader with proven management experience and a passion for making a difference in the community. The Regional Manager in The Villages, FL, oversees daily operations of the region, is organized and decisive, and can motivate the team to reach daily and long-range blood collection goals. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

Medical Director (Memorial Blood Centers). Memorial Blood Centers (MBC.ORG), a division of Innovative Blood Resources, now a major partner in the NYBC Enterprise, has been saving and sustaining lives since 1948, and we're seeking a Medical Director who will help further our efforts and expand our success. This challenging medical directorship serves as co-medical director at a nationally recognized Children's hospital transfusion service, a national quality leading safety net hospital that is the largest local level 1 trauma center (both adult and pediatric), and associate medical director for blood centers

in Minnesota (Duluth and Twin Cities, Nebraska (Lincoln and Omaha) and Greater Kansas City (Kansas and Missouri). The role will provide medical support across the Enterprise and for the assigned blood centers and transfusion services. Memorial Blood Centers supplies blood and blood components, state-of-the-art laboratory services, and biomedical expertise to area healthcare partners, national blood centers, biotechnology companies, research institutions, and international clients. The blood centers in Minnesota, Nebraska and the Greater Kansas City area serve nearly 100 hospitals and more than a dozen air ambulances with life-saving blood. Ample opportunity for research and clinical publication as well as direct patient and donor involvement. Click here to apply: <https://www.kleinherhsh.com/positions/medical-director-2/>.

Director, Public Relations and Marketing. Mississippi Blood Services (MBS) is seeking the right candidate for the highly visible position of Director of Public Relations & Marketing. We are looking for an individual with flexible skills who can oversee our Communications and Public Relations efforts to ensure we are able to collect and distribute the much-needed resource of blood donations! As the face of the company, the ideal candidate will be responsible for all aspects of Public Relations and Marketing, which includes recruitment of blood drives and telerecruitment. This individual will work with Public Relations, Marketing Representatives, Telerecruitment manager, and other managers to coordinate and organize ample daily collections of whole blood, double red cells, apheresis platelets, and plasma collections for the organization. They will also work in conjunction with other MBS management to set strategic goals and objectives for the company. Must have a bachelor's degree (BA) from a four-year college or university; three to five years' related experience; or equivalent combination of education and experience. Visit www.msblood.com to apply online.

Purchasing Manager. LifeSouth Community Blood Centers is seeking a highly skilled leader with proven management experience and a passion for making a difference. The Purchasing Manager at our headquarters location in Gainesville, FL is responsible for vendor selection, negotiation, establishment and maintenance of all purchased materials, supplies, equipment, and services used by the company. The Purchasing Manager oversees daily operations of the Purchasing team, is organized and decisive, and can motivate the team to reach daily and long-range goals. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and apply [here!](#) 💧